Hubei Biocause Pharmaceutical Overview

  • Year Founded
  • 1993

Year Founded

  • Status
  • Public

  • Employees
  • 1,765

Employees

  • Stock Symbol
  • 000627

Stock Symbol

  • Investments
  • 6

  • Share Price
  • $0.36
  • (As of Tuesday Closing)

Hubei Biocause Pharmaceutical General Information

Description

Hubei Biocause Pharmaceutical Co Ltd is a China-based company engaged in life insurance, health insurance, accident insurance, and other life insurance businesses, medicine, and chemical businesses. The company generates its revenue in the form of premiums.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • No.122 Yangwan Road
  • Jingmen
  • Hubei, 448000
  • China
+86 027
Primary Industry
Pharmaceuticals
Other Industries
Other Chemicals and Gases
Stock Exchange
SHE
Vertical(s)
Corporate Office
  • No.122 Yangwan Road
  • Jingmen
  • Hubei, 448000
  • China
+86 027

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Hubei Biocause Pharmaceutical Stock Performance

As of 08-Jul-2025, Hubei Biocause Pharmaceutical’s stock price is $0.36. Its current market cap is $1.78B with 4.9B shares.

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.36 $0.38 $0.22 - $0.75 $1.78B 4.9B 67M -$0.02

Hubei Biocause Pharmaceutical Financials Summary

As of 30-Sep-2024, Hubei Biocause Pharmaceutical has a trailing 12-month revenue of $5.86B.

In Thousands,
USD
TTM 30-Sep-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 4,390,753 3,766,320 4,155,964 4,846,148
Revenue 5,862,554 7,009,736 7,315,139 7,615,719
EBITDA (237,276) (242,496) 55,245 73,882
Net Income (107,531) (92,123) 40,693 72,899
Total Assets 40,664,778 42,594,579 41,830,141 41,402,546
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Hubei Biocause Pharmaceutical Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Hubei Biocause Pharmaceutical Investments & Acquisitions (6)

Hubei Biocause Pharmaceutical’s most recent deal was a Later Stage VC with Pharnex. The deal was made on 09-May-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Pharnex 09-May-2024 Later Stage VC Media and Information Services (B2B)
Granules Biocause Pharmaceuticals 04-Feb-2020 Secondary Transaction - Private Drug Discovery
Guohua Life Insurance 30-Aug-2019 Secondary Transaction - Private Life and Health Insurance
Guohua Life Insurance 22-Mar-2016 Merger/Acquisition Life and Health Insurance
AXA Tianping Property Insurance 10-Mar-2016 Secondary Transaction - Private Multi-line Insurance
You’re viewing 5 of 6 investments and acquisitions. Get the full list »

Hubei Biocause Pharmaceutical ESG

Risk Overview

Risk Rating

Updated June, 20, 2025

43.8 | Severe Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,697

Rank

Percentile

Pharmaceuticals

Industry

of 847

Rank

Percentile

Pharmaceuticals

Subindustry

of 420

Rank

Percentile

To view Hubei Biocause Pharmaceutical’s complete esg history, request access »

Hubei Biocause Pharmaceutical Exits (1)

Hubei Biocause Pharmaceutical’s most recent exit was on 10-Mar-2016 from AXA Tianping Property Insurance. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
AXA Tianping Property Insurance 10-Mar-2016 Completed
To view Hubei Biocause Pharmaceutical’s complete exits history, request access »

Hubei Biocause Pharmaceutical Affiliates

Subsidiaries (2)

Name Industry Location Year Founded
Guohua Life Insurance Shanghai, China 2007
Granules Biocause Pharmaceuticals Jingmen, China 2007

Hubei Biocause Pharmaceutical FAQs

  • When was Hubei Biocause Pharmaceutical founded?

    Hubei Biocause Pharmaceutical was founded in 1993.

  • Where is Hubei Biocause Pharmaceutical headquartered?

    Hubei Biocause Pharmaceutical is headquartered in Hubei, China.

  • What is the size of Hubei Biocause Pharmaceutical?

    Hubei Biocause Pharmaceutical has 1,765 total employees.

  • What industry is Hubei Biocause Pharmaceutical in?

    Hubei Biocause Pharmaceutical’s primary industry is Pharmaceuticals.

  • Is Hubei Biocause Pharmaceutical a private or public company?

    Hubei Biocause Pharmaceutical is a Public company.

  • What is Hubei Biocause Pharmaceutical’s stock symbol?

    The ticker symbol for Hubei Biocause Pharmaceutical is 000627.

  • What is the current stock price of Hubei Biocause Pharmaceutical?

    As of 08-Jul-2025 the stock price of Hubei Biocause Pharmaceutical is $0.36.

  • What is the current market cap of Hubei Biocause Pharmaceutical?

    The current market capitalization of Hubei Biocause Pharmaceutical is $1.78B.

  • What is Hubei Biocause Pharmaceutical’s current revenue?

    The trailing twelve month revenue for Hubei Biocause Pharmaceutical is $5.86B.

  • What is Hubei Biocause Pharmaceutical’s annual earnings per share (EPS)?

    Hubei Biocause Pharmaceutical’s EPS for 12 months was -$0.02.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »